Meningitis incidence and mortality declined significantly in the Western Pacific Region from 1990 to 2023 following expanded vaccination initiatives.

Nirsevimab immunization effectively decreases the risk for RSV-related LRTI hospitalizations in an infant's first year.

Coadministration of the MenACYW-TT vaccine with routine pediatric immunizations is well tolerated among healthy infants and ...

Updated BNT162b2 KP.2 vaccination reduces COVID-19 hospitalizations and ED visits in immunocompetent adults regardless of risk status.

Long-term data suggest that patients with pneumococcal meningitis originating from hematogenous spread experience the highest rates of 30-day mortality, though the overall burden of resistant disease ...

Adults with HIV aged 60 years and older are more likely to report favorable quality of life (QOL) following a switch in antiretroviral therapy (ART) than adults younger than 60 ye ...

Real-world data demonstrate that nirsevimab and maternal vaccination protect infants against severe RSV outcomes.

MenB coverage was improved but still suboptimal among individuals aged 10 to 25 years who had high-risk conditions, with an overall initiation rate of 39%. Patients with asplenia were most likely to ...